Opus Genetics (IRD) Retained Earnings (2010 - 2026)

Opus Genetics (IRD) has 17 years of Retained Earnings data on file, last reported at $208.3 million in Q1 2026.

• On a quarterly basis, Retained Earnings rose 36.79% year-over-year to $208.3 million in Q1 2026; TTM through Mar 2026 was $208.3 million, a 36.79% increase from a year earlier, with the FY2025 full-year figure at $203.9 million, up 39.95% from the prior year.
• Retained Earnings for Q1 2026 stood at $208.3 million, up from $203.9 million in the prior quarter.
• Over the last five years, Retained Earnings for IRD reached as high as $208.3 million in Q1 2026 and fell as low as -$172.1 million in Q3 2025.
• Historically, Retained Earnings has averaged $84.4 million across 5 years, with a median of $119.9 million in 2023.
• Across the five-year window, Retained Earnings jumped 283.79% in 2023 and plunged 224.54% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$71.5 million in 2022, then soared by 283.79% to $131.4 million in 2023, then advanced by 10.92% to $145.7 million in 2024, then surged by 39.95% to $203.9 million in 2025, then rose by 2.13% to $208.3 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $208.3 million in Q1 2026, $203.9 million in Q4 2025, and -$172.1 million in Q3 2025.